Legemiddeldosering ved mage- og tarmsykdom, leversykdom, hjertesykdom og nevrologisk sykdom

Helsebiblioteket, emnebibliotek legemidler, preparatomtaler (SPC) www.helsebiblioteket.no/legemidler 

European Medicines Agency (EMA), EPARs for authorised medicinal products for human use www.ema.europa.eu/htms/human/epar/a.htm 

British National Formulary (BNF) 62 September 2011. ISBN 978-0-85369-981-1 www.bnf.org 

McDonagh T, Metro M, Adamo M et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2021. The 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (2021) 00, 1128. ESC GUIDELINES doi:10.1093/eurheartj/ehab36 

Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ,Bart BA, Mascette AM, Braunwald E, O’Connor CM. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364: 797–805 

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312–2318 

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11–21 

McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Pina IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710–721 

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA. Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840–1848 

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004;10:155–164 

Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Cyclo-oxygenase-2 inhibitors versus non-selective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751–1756 

Pollack, CV, Reilly, PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 372: Epub ahead of print Nevro-NEL. Norsk nevrologisk forenings prosedyrer 2021. https://nevrologi.legehandboka.no/ 

Elsais A, Popperud TH, Melien Ø, Kerty E. Medikamenter som kan utløse og forverre myasthenia gravis. Tidsskr Nor Legeforen 2013; 133: 296-9. 

Henning OJ, Nakken KO. Psychiatric comorbidity and use of psychotropic drugs in epilepsy patients. Acta Neurol Scand Suppl 2010; 190: 18-22 

Perez-Lloret S, Rascol O. Parkinson disease: serotonin reuptake inhibitors for depression in PD. Nature reviews Neurol 2012; 5 juni (e-pub ahead of print) 

Kim H, Kim SH, Kim JB. Antihistamines as a common cause of new-onset seizures: a single-center observational study. Neurol Sci. 2021 Jun;42(6):2505-2508. doi: 10.1007/s10072-021-05043-2 

Kyle K, Bronstein JM. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review. Parkinsonism Relat Disord. 2020;75:55-62. doi: 10.1016/j.parkreldis.2020.05.026 

Ryan M, Eatmon CV, Slevin JT. Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother. 2019;20(11):1351-1363. doi: 10.1080/14656566.2019.1612877. 

Sheikh S, Alvi U, Soliven B, Rezania K. Drugs that induce or cause deterioration of myasthenia gravis. J Clin Med 2021, 10, 1537 (pp 1-20). https://doi.org/10.3390/jcm10071537 

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2015;36(33):2239-45. 

Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. British journal of clinical pharmacology. 2016;82(6):1591-600. 

Steffel J, Collings R, Antz M et al.: 2021 European Heart Rhythm Association (EHRA) Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace (2021) 00, 1–65 POSITION PAPER doi:10.1093/europace/euab065 

Nevro-NEL. Norsk nevrologisk forenings prosedyrer 2021. https://nevrologi.legehandboka.no/